Drug intelligence / Profile preview

Bonipar

Development stage: Phase 2
Lead developer: Duke University
Modality: Small Molecules
Administration: Topical

Overview

**Bonipar** is an investigational topical analgesic spray formulated with camphor, methyl salicylate, and coconut, eucalyptus, nutmeg, and rosemary oils. It was evaluated for acute and chronic localized musculoskeletal pain in a completed randomized non-inferiority study against diclofenac sodium 1.5% topical solution; the published analysis reported non-inferior pain-reduction outcomes and a comparable onset of analgesia. ([scholars.duke.edu](https://scholars.duke.edu/publication/1646435))

Brand names: Bonipar

Beyond the preview

Go deeper on Bonipar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bonipar.

Explore the full profile